Wakabayashi T, Kajita Y, Hatano N, Thompson T, Nagasaka T, Yoshida J
Department of Neurosurgery, Nagoya University School of Medicine, Japan.
Brain Tumor Pathol. 2000;17(1):29-33. doi: 10.1007/BF02478915.
The retrospective clinicopathological characteristics of oligodendroglial tumors were investigated in patients who underwent surgery, radiotherapy, and/or chemotherapy. Regarding oligodendroglioma and oligoastrocytoma without malignancy, patients who had undergone radiation therapy at a total dose of 40-50Gy had relatively long postoperative survival. Of these 15 patients, 6 showed signs of recurrence, and after additional treatment, 5 patients are still alive. On the other hand, regarding anaplastic oligodendroglial tumors, patients with anaplastic oligoastrocytoma responded well to combination chemotherapy with interferon beta, nitrosourea derivatives (ACNU/ MCNU), and radiation therapy (referred to as IAR/IMR) and survived longer than patients with anaplastic oligodendroglioma. In conclusion, patients with oligodendroglial tumors could survive longer by treatment involving surgery and radiotherapy. As for malignancy, cases of anaplastic oligoastrocytoma could be effectively treated by adjuvant therapy using IAR/IMR after surgery, but in cases of anaplastic oligodendroglioma, the response to IAR/IMR was not good, and another strategy of treatment should be recommended.
对接受手术、放疗和/或化疗的少突胶质细胞瘤患者的回顾性临床病理特征进行了研究。对于无恶性的少突胶质细胞瘤和少突星形细胞瘤，接受总剂量40 - 50Gy放射治疗的患者术后生存期相对较长。在这15例患者中，6例出现复发迹象，经过额外治疗后，5例患者仍然存活。另一方面，对于间变性少突胶质细胞瘤，间变性少突星形细胞瘤患者对干扰素β、亚硝基脲衍生物（ACNU/MCNU）联合放疗（称为IAR/IMR）反应良好，并且比间变性少突胶质细胞瘤患者存活时间更长。总之，少突胶质细胞瘤患者通过手术和放疗相结合的治疗可以存活更长时间。至于恶性肿瘤，间变性少突星形细胞瘤病例在手术后使用IAR/IMR辅助治疗可以得到有效治疗，但对于间变性少突胶质细胞瘤病例，对IAR/IMR的反应不佳，应推荐另一种治疗策略。
